

**AMENDMENTS TO THE CLAIMS**

1. (Cancelled)

2. (Currently Amended) The ~~composition of claim 1~~ method of treating tear abnormality of claim 12, wherein the treatment of the tear abnormality is achieved by an improvement in the stability of a tear layer and/or an improvement in the retention of tear on the keratoconjunctive.

3. (Currently Amended) The ~~composition of claim 2~~ method of treating tear abnormality of claim 2, wherein the improvement in the stability of the tear layer is achieved by inhibition of evaporation of tear.

4. (Currently Amended) The ~~composition of claim 2~~ method of treating tear abnormality of claim 2, wherein the improvement in the stability of the tear layer is achieved by an improvement in tear layer breakup time.

5. (Currently Amended) The ~~composition of claim 2~~ method of treating tear abnormality of claim 2, wherein the improvement in the retention of tear is achieved by retention of keratoconjunctive epithelium cells in a normal state and/or restoration of the keratoconjunctive epithelium cells to the normal state.

6. **(Currently Amended)** The composition of claim 2 method of treating tear abnormality of claim 2, wherein the improvement in the retention of tear is achieved by retention of the microvilli/microfolds of keratoconjunctive epithelium cells in a normal state and/or restoration of the microvilli/microfolds of the keratoconjunctive epithelium cells to the normal state.

7. **(Currently Amended)** The composition of claim 1 method of treating tear abnormality of claim 12, wherein the tear abnormality is tear abnormality without impairments on the keratoconjunctive.

8. **(Currently Amended)** The composition of claim 1 method of treating tear abnormality of claim 12, wherein the treatment of the tear abnormality is inhibition of the occurrences of diseases caused by the tear abnormality.

9. **(Currently Amended)** The composition of claim 8 method of treating tear abnormality of claim 8, wherein the treatment of the tear abnormality is inhibition of the occurrences of diseases caused by the tear abnormality without impairments on the keratoconjunctive.

10. **(Currently Amended)** The composition of claim 1 method of treating tear abnormality of claim 12, wherein the concentration of 3-hydroxybutyric acid and/or salts thereof is 0.8 to 800 mmol/l.

11. **(Currently Amended)** The composition of claim 1 method of treating tear abnormality of claim 12, wherein the concentration of 3-hydroxybutyric acid and/or salts thereof is 10 to 150 mmol/l.

12. **(Currently Amended)** A method for treating tear abnormality in a patient suffering from a tear abnormality, which comprises:

applying the composition of claim 1 administering to a patient having at least one tear abnormality selected from the group consisting of hypolacrimation, alacrima, xerophthalmia, Sjogren's syndrome, Stevens-Johnson syndrome, ocular pemphigus, marginal blepharitis, dysfunctions of lidaperture and sensory nerves, dry eye associated with allergic conjunctivitis and viral conjunctivitis, as eye drops an ophthalmological composition comprising 3-hydroxybutyric acid and/or salts thereof as an active ingredient in an amount effective in treating the tear abnormality.

13. – 14. **(Cancelled)**

15. **(New)** A method for treating tear abnormality of claim 12, wherein said ophthalmological composition is administered as one to three eye drops, one to twenty times per day.

16. (New) A method for treating tear abnormality of claim 15, wherein said eye drops are administered one to ten times per day.